Yesterday, Danaher reported Life Sciences revenues rose nearly 5 percent in Q3 2024 relative to Q3 2023, as did their Diagnostics revenues.  However, when including Core revenues, Danaher projected an overall single digit revenue decline in the 4^th quarter and for the full year for the company.  The Life Sciences and Diagnostics increases for the large conglomerate are a hopeful sign of recovery from the difficult 2023-24 stretch for the bio-tools sector. – Source: Danaher; Genome Web